Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more
Santhera Pharmaceuticals Holding AG - Asset Resilience Ratio
Santhera Pharmaceuticals Holding AG (SPHDF) has an Asset Resilience Ratio of 83.08% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2023)
This chart shows how Santhera Pharmaceuticals Holding AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Santhera Pharmaceuticals Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.64 Million | 83.08% |
| Total Liquid Assets | $66.64 Million | 83.08% |
Asset Resilience Insights
- Very High Liquidity: Santhera Pharmaceuticals Holding AG maintains exceptional liquid asset reserves at 83.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Santhera Pharmaceuticals Holding AG Industry Peers by Asset Resilience Ratio
Compare Santhera Pharmaceuticals Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Santhera Pharmaceuticals Holding AG (2006–2023)
The table below shows the annual Asset Resilience Ratio data for Santhera Pharmaceuticals Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 5.23% | $5.74 Million | $109.63 Million | +6.59pp |
| 2018-12-31 | -1.36% | $-1.50 Million | $110.29 Million | -13.21pp |
| 2017-12-31 | 11.85% | $13.01 Million | $109.78 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $90.79 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $117.15 Million | -- |
| 2007-12-31 | 0.06% | $81.00K | $144.18 Million | -0.11pp |
| 2006-12-31 | 0.16% | $263.00K | $162.39 Million | -- |